Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis

Company Overview

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.

Key Stats

• Today's Range: C$2.81 to C$2.92
• 50-Day Range: C$2.56 to C$3.12
• 52-Week Range: C$1.71 to C$5.56
• Volume: 25,510 shs
• Average Volume: 67,081 shs
• Market Capitalization: C$92.58 million
• P/E Ratio: 143.50
• Dividend Yield: N/A
• Price Target: C$4.57
• Consensus Rating: Buy

Medexus Pharmaceuticals Stock Analysis - MarketRank™

Medexus Pharmaceuticals scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Buy

Consensus Rating

Medexus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Upside Potential

Medexus Pharmaceuticals has a consensus price target of C$4.57, representing about 59.1% upside from its current price of C$2.87.

Amount of Analyst Coverage

Medexus Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Medexus Pharmaceuticals is 143.50, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.49.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medexus Pharmaceuticals is 143.50, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.00.

Price to Book Value per Share Ratio

Medexus Pharmaceuticals has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for MDP.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medexus Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Medexus Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for MDP.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.34

News Sentiment

Medexus Pharmaceuticals has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Medexus Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

8 people have searched for MDP on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.

MarketBeat Follows

1 people have added Medexus Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Medexus Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.14% of the stock of Medexus Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 0.78% of the stock of Medexus Pharmaceuticals is held by institutions.

MDP Stock Analysis - Frequently Asked Questions

How have MDP shares performed this year?

Medexus Pharmaceuticals' stock was trading at C$3.46 at the beginning of the year. Since then, MDP shares have decreased by 17.1% and is now trading at C$2.87.

How do I buy shares of Medexus Pharmaceuticals?

Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Medexus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Medexus Pharmaceuticals investors own include AutoZone (AZO), Cisco Systems (CSCO), Facedrive (FDVRF), Intel (INTC), kneat.com (KSI), NIO (NIO) and Nanotech Security (NTS).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:MDP
• CIK: N/A
• Web: www.medexus.com
• Phone: 877-633-3987
• Fax: N/A
• Employees: 98
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Medexus Pharmaceuticals: C$4.57
• High Price Target: C$6.25
• Low Price Target: C$3.45
• Potential Upside/Downside: +59.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): C$0.02
• Trailing P/E Ratio: 143.50
• Forward P/E Ratio: 17.57
• P/E Growth: N/A
• Net Income: C$3.26 million
• Net Margins: 3.25%
• Pretax Margin: N/A
• Return on Equity: 11.07%
• Return on Assets: 4.89%

Debt

• Debt-to-Equity Ratio: 120.58
• Current Ratio: 1.01
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: C$105.66 million
• Price / Sales: 0.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: C$1.35 per share
• Price / Book: 2.12

Miscellaneous

• Outstanding Shares: 32,258,000
• Free Float: N/A
• Market Cap: C$92.58 million
• Optionable: Not Optionable
• Beta: 1.60